211 related articles for article (PubMed ID: 33878394)
1. Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.
Chaudhary S; Pothuraju R; Rachagani S; Siddiqui JA; Atri P; Mallya K; Nasser MW; Sayed Z; Lyden ER; Smith L; Gupta SD; Ralhan R; Lakshmanan I; Jones DT; Ganti AK; Macha MA; Batra SK
Cancer Lett; 2021 Jul; 510():79-92. PubMed ID: 33878394
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
[TBL] [Abstract][Full Text] [Related]
3. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
Zhou J; Wu Z; Wong G; Pectasides E; Nagaraja A; Stachler M; Zhang H; Chen T; Zhang H; Liu JB; Xu X; Sicinska E; Sanchez-Vega F; Rustgi AK; Diehl JA; Wong KK; Bass AJ
Nat Commun; 2017 Jan; 8():13897. PubMed ID: 28059068
[TBL] [Abstract][Full Text] [Related]
5. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
Beck TN; Georgopoulos R; Shagisultanova EI; Sarcu D; Handorf EA; Dubyk C; Lango MN; Ridge JA; Astsaturov I; Serebriiskii IG; Burtness BA; Mehra R; Golemis EA
Mol Cancer Ther; 2016 Oct; 15(10):2486-2497. PubMed ID: 27507850
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
7. Molecular homology between canine spontaneous oral squamous cell carcinomas and human head-and-neck squamous cell carcinomas reveals disease drivers and therapeutic vulnerabilities.
Guscetti F; Nassiri S; Beebe E; Rito Brandao I; Graf R; Markkanen E
Neoplasia; 2020 Dec; 22(12):778-788. PubMed ID: 33142242
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo.
Li R; Wang Q; Zhao Y; Zhu Y; Wang X
Mol Biol Rep; 2024 Mar; 51(1):455. PubMed ID: 38536540
[TBL] [Abstract][Full Text] [Related]
9. Letter to the editor regarding "Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.".
Liang R
Cancer Lett; 2022 Feb; 527():191-192. PubMed ID: 35115094
[No Abstract] [Full Text] [Related]
10. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Michel L; Ley J; Wildes TM; Schaffer A; Robinson A; Chun SE; Lee W; Lewis J; Trinkaus K; Adkins D
Oral Oncol; 2016 Jul; 58():41-8. PubMed ID: 27311401
[TBL] [Abstract][Full Text] [Related]
12. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
van Caloen G; Machiels JP
Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
14. Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma.
Hu Q; Peng J; Jiang L; Li W; Su Q; Zhang J; Li H; Song M; Cheng B; Xia J; Wu T
Cell Death Dis; 2020 Oct; 11(10):925. PubMed ID: 33116117
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
16. Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo.
Zhu L; Luo Q; Bi J; Ding J; Ge S; Chen F
Chem Biol Interact; 2014 Dec; 224():149-56. PubMed ID: 25450235
[TBL] [Abstract][Full Text] [Related]
17. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
Kalu NN; Johnson FM
Expert Opin Investig Drugs; 2017 Feb; 26(2):207-217. PubMed ID: 28042706
[TBL] [Abstract][Full Text] [Related]
18. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas.
Duah E; Seligson ND; Persaud AK; Dam Q; Pabla N; Rocco JW; Li J; Poi M
Mol Carcinog; 2023 Aug; 62(8):1201-1212. PubMed ID: 37132760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
